ATXI: Avenue Therapeutics, Inc. Stock

by  •  • Comments Off on ATXI: Avenue Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 1.32
Enterprise Value ($M) -2.21
Book Value ($M) 1.86
Book Value / Share 0.59
Price / Book 0.71
NCAV ($M) 1.86
NCAV / Share 0.59
Price / NCAV 0.71

Profitability (mra)
Return on Invested Capital (ROIC) -6.28
Return on Assets (ROA) -3.52
Return on Equity (ROE) -6.14

Liquidity (mrq)
Quick Ratio 3.27
Current Ratio 3.27

Balance Sheet (mrq) ($M)
Current Assets 2.67
Assets 2.67
Liabilities 0.82
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -11.28
Net Income -11.65
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -9.03
Cash from Investing 0.00
Cash from Financing 9.84

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
04-02 13D/A Fortress Biotech, Inc. 10.30 11.43
02-14 13G/A Armistice Capital, Llc 4.99 -12.70
02-14 13G Ikarian Capital, LLC 6.80
05-02 13G/A Davidow Robert L 2.90 -98.69

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-31 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)

Similar Companies
ARSUF – Fagron NV ATHXQ – Athersys, Inc.
ATRX – Adhera Therapeutics, Inc. AVRW – Avenir Wellness Solutions, Inc.
AVVH – AVVAA World Health Care Products, Inc.


Financial data and stock pages provided by
Fintel.io